[ad_1]
FILE PHOTO: The Allergan logo is seen in this photo illustration November 23, 2015. To match special report USA-FDA/CASES REUTERS/Thomas White/Illustration/File Photo
(Reuters) – Allergan Plc said on Wednesday its experimental add-on treatment for major depressive disorder failed to meet the main goals of three late-stage studies.
The trials evaluated the efficacy, safety and tolerability of Allergan’s treatment, rapastinel, compared to a placebo, both in combination with antidepressant therapy (ADT) in patients with depression who had a partial response to ADT, the company said.
Reporting by Manogna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila
Our Standards:The Thomson Reuters Trust Principles.
[ad_2]
Source link